Xy Capital LTD Bei Gene, Ltd. Transaction History

Xy Capital LTD

$292 Billion
Q3 2024

A detailed history of Xy Capital LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Xy Capital LTD holds 30,464 shares of BGNE stock, worth $5.93 Million. This represents 2.34% of its overall portfolio holdings.

Number of Shares

30,464

Holding current value

$5.93 Million

% of portfolio

2.34%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$143.93 - $224.51 $4.38 Million - $6.84 Million	30,464 New	30,464 $6.84 Billion
Q1 2024 Apr 29, 2024	BUY	$141.8 - $181.47 $4.2 Million - $5.37 Million	29,616 New	29,616 $4.63 Billion
Q3 2023 Nov 01, 2023	BUY	$179.87 - $225.13 $2.56 Million - $3.2 Million	14,235 Added 1205.33%	15,416 $2.77 Billion
Q2 2023 Jul 28, 2023	SELL	$178.3 - $266.78 $1.51 Million - $2.27 Million	-8,496 Reduced 87.8%	1,181 $211 Million
Q1 2023 May 08, 2023	BUY	$215.53 - $274.5 $1 Million - $1.28 Million	4,659 Added 92.85%	9,677 $2.09 Billion
Q4 2022 Feb 09, 2023	BUY	$125.51 - $229.3 $629,809 - $1.15 Million	5,018 New	5,018 $1.1 Billion

Others Institutions Holding BGNE

# of Institutions

250

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$2.06 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.25 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$1.01 Billion
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$968 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$721 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xy Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xy Capital LTD with notifications on news.

Account